ADC Therapeutics SA announced that, on December 15, 2022, Robert A. Schmidt informed the Company of his resignation as the Company's Chief Accounting Officer, effective December 30, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.3 USD | +4.43% | -3.51% | +98.80% |
05-30 | Cantor Fitzgerald Initiates ADC Therapeutics at Overweight Rating | MT |
05-07 | HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+98.80% | 318M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- ADCT Stock
- News ADC Therapeutics SA
- ADC Therapeutics SA Announces Resignation of Robert A. Schmidt as Company’S Chief Accounting Officer, Effective December 30, 2022